Figure 1 | Scientific Reports

Figure 1

From: RNA editing facilitates the enhanced production of neoantigens during the simultaneous administration of oxaliplatin and radiotherapy in colorectal cancer

Figure 1

ADAR1 is upregulated in CMS1 and MSI CRCs. (A) Expression analysis of CD8, PD-1, and PD-L1 in CRC was performed using the TCGA database. Vertical axis shows RSEM (batch normalized from Illumina HiSeq_RNASeqV2). Patients were classified as CMS1–4 according to the consensus molecular subtypes. CMS1 has a strong immune activation effect, showing upregulation of CD8, the surface marker of cytotoxic T cells (p < 0.01). Additionally, PD-1 and PD-L1 (both p < 0.001) are upregulated in CMS1 CRCs. Steel test. (B) ADAR1 was upregulated to a larger extent in CMS1 CRCs compared with its expression in other subtypes (p < 0.01). However, amplification levels of ADAR1 did not differ between each subtype. Steel test. (C) ADAR1 was upregulated in MSI CRCs compared with its expression in MSS CRCs (p < 0.001). Wilcoxon’s signed rank test. (D) ADAR1 showed a positive correlation with CD8 (ρ = 0.50, p < 0.001), PD-1 (ρ = 0.51, p < 0.001), and PD-L1 (ρ = 0.61, p < 0.001). **p < 0.01; ***p < 0.001.

Back to article page